TOTAL N: 422 MORTAL N=51 NON-MORTAL N=371
P değeri
Age (median) (min-max) 55,5±15,4 (18,0-91,0) 65,5 (36,0-91,0) 54,0 (18,0-88,0) <0,001
Age group(n,%) <50 age 50-64 age ≥ 65 age 151 (35,8%) 151 (35,8%) 120 (28,4%) 2 (%3,9) 23 (%45,1) 26 (%51,0) 149 (%40,2) 128 (%34,5) 94 (%25,3)
<0,001
Gender (n,%) Male Female 252 (59,7%) 170 (40,3%) 37 (%72,5) 14 (%27,5) 215 (%58,0) 156 (%42,0)
0,046
BMI (median) (min-max) 26,3±4,2 (16,8-46,9) 24,5 (18,9-39,2) 25,4 (16,8-46,9) 0,142
BMI group (n,%) Thin Normal Preobese Obese 5 (%1,2) 189 (%44,8) 156 (%37,0) 72 (%17,1) 0 (%0,0) 26 (%51,0) 20 (%39,2) 5 (%9,8) 5 (%1,3) 163 (%43,9) 136 (%36,7) 67 (%18,1)
0,383
Obesity (n,%) 72 (17,0 %) 5 (%9,8) 67 (%18,1) 0,142
Overweight (n,%) 51 (12,0%) 25 (%49,0) 26 (%51,0) 0,444
Cigarette (n,%) Smoker Exsmoker Nonsmoker 64 (%15,2) 119 (%28,2) 239 (%56,6) 5 (%9,8) 32 (%62,7) 14 (%27,5) 59 (%15,9) 87 (%23,5) 225 (%60,6)
<0.001
Cigarette (n,%) Ever smoker Non smoker 183 (43,3%) 239 (56,6%) 37 (%72,5) 14 (%27,5) 146 (%39,4) 225 (%60,6)
<0,001
Blood Group (n,%) A B AB 0 174 (%41,2) 74 (%17,5) 52 (%12,3) 122 (%28,9) 16 (%31,4) 9 (%17,6) 11 (%21,6) 15 (%29,4) 158 (%42,6) 65 (%17,5) 41 (%11,1) 107 (%28,8)
0,145
Pneumonia (n,%) Mild Middle Severe 182 (%43,1) 153 (%36,3) 87 (%20,6) 8 (%15,7) 2 (%3,9) 41 (%80,4) 174 (%46,9) 151 (%40,7) 46 (%12,4)
<0.001
PCR (n,%) Positive Negative 306 (72,5%) 116 (27,4%) 45 (%88,2) 6 (%11,8) 261 (%70,4) 110 (%29,6)
0,007
Comorbidity (n,%) yes No 234 (%55,5) 188 (%44,5) 42 (%82,4) 9 (%17,6) 192 (%51,8) 179 (%48,2)
<0.001
Comorbidity (n,%) No Single Multiple 188 (%44,5) 118 (%28,0) 116 (%27,5) 9 (%17,6) 19 (%37,3) 23 (%45,1) 179 (%48,2) 99 (%26,7) 93(%25,1)
<0.001
COPD(n,%) 64 (%15,2) 14 (%27,5) 50 (%13,5) 0,009
Cardiac Diseases (n,%) 70 (%16,6) 14 (%27,5) 56 (%15,1) 0,026
Hypertansion (n,%) 109 (%25,8) 19 (%37,3) 90 (%24,3) 0,047
Diabetius mellitus(n,%) 64 (%15,2) 11 (%21,6) 53 (%14,3) 0,174
Asthma(n,%) 19 (%4,5) 3 (%5,9) 16 (%4,3) 0,612
Serebrovasculer disease (n,%) 18 (%4,3) 4 (%7,8) 14 (%3,8) 0,178
Malignancy (n,%) 53 (%12,6) 19 (%37,3) 34 (%9,2) <0,001
Using ACE Inhbitor (n,%) Present Absent 105 (%24,9) 317 (%75,1) 21 (%41,2) 30 (%58,8) 84 (%22,6) 287 (%77,4)
0,004
Radyological progression (n,%) Present Absent 68 (16,1%) 349 (82,7%) 35 (%68,6) 16 (%31,4) 33 (%9,0) 333 (%91,0)
<0,001